rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    MESO
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Mesoblast stock hits 52-week low at 11.89 USD
      Nov 17Investing.comMESO
      Mesoblast Posts $115 Million in Revenue, Sets Sights on 2027 Back Pain Trial Readout
      Nov 12Yahoo FinanceMESO
      Top 3 Australian Founder Led Stocks With Revenue Growth Up To 38%

      Tech-heavy indices are sliding after concerns about stricter rules on AI data centres and chipmakers, yet many Australian businesses built and still run by their original founders are not priced on AI hype at all. These leaders often think in decades, not quarters, and keep meaningful skin in the game. This article highlights three founder-led Australian stocks from our screener that show how that long-term mindset can reshape both risk and reward. The three stocks highlighted here offer a...

      Nov 6Yahoo FinanceMESO
      Ryoncil Growth Could Change The Case For Mesoblast Stock
      Oct 29Yahoo FinanceMESO
      12 Health Care Stocks Moving In Thursday's Pre-Market Session
      Oct 29BenzingaMESO
      Australian Shares Close Higher; Mesoblast Rallies After Posting Revenue Growth

      Australian shares closed higher on Thursday, tracking Wall Street gains after the US Federal Reserve

      Oct 29Yahoo FinanceMESO
      Inside Biotech: Mesoblast surges 24% as Ryoncil sales climb and cash spend falls sharply

      Mesoblast Ltd (ASX:MSB, NASDAQ:MESO) shares surged nearly 24% to $2.33 in afternoon trading after the cell therapy developer reported strong first-quarter revenue growth and a sharp reduction in operating cash spend. The US-focused biotechnology group reported Ryoncil net revenue of US$28...

      Oct 29Yahoo FinanceMESO
      State Street Entities Exit Substantial Holder Position in Mesoblast

      Detailed price information for Mesoblast Ltd (MEOBF) from The Globe and Mail including charting and trades.

      Oct 27The Globe and MailMESO
      Mesoblast: Ryoncil Helps Fund Rexlemestrocel-L For Back Pain (NASDAQ:MESO)

      Mesoblast's Ryoncil provides commercial validation for its cell-therapy platform while helping finance additional development. Learn more about MESO stock here.

      Oct 19Seeking AlphaMESO
      Mesoblast Ltd ADR stock hits 52-week low at 13.03 USD
      Oct 16Investing.comMESO
      Mesoblast Posts First Full-Year Ryoncil Revenue Surge and Files 2026 Annual Report

      Detailed price information for Mesoblast Ltd ADR (MESO-Q) from The Globe and Mail including charting and trades.

      Oct 14The Globe and MailMESO
      Mesoblast Ltd (MEOBF) Statistics

      Find out all the key statistics for Mesoblast Ltd (MEOBF), including valuation measures, fiscal year financial statistics, trading record, share statistics and more.

      Oct 2The Globe and MailMESO
      Wall Street Analysts Are Bullish on Top Healthcare Picks

      Detailed price information for Mesoblast Ltd (MEOBF) from The Globe and Mail including charting and trades.

      Sep 28The Globe and MailMESO
      Mesoblast wins FDA nod for new potency assay for Ryoncil
      Sep 24Seeking AlphaMESO
      Cantor Fitzgerald reiterates Mesoblast stock rating on adult trial focus
      Sep 24Investing.comMESO
      Mesoblast receives FDA approval for new potency assay for Ryoncil
      Sep 24Investing.comMESO
      Mesoblast Gets FDA Approval for New Ryoncil Potency Assay

      Mesoblast (MESO) said Thursday that the US Food and Drug Administration approved a new potency assay

      Sep 24Yahoo FinanceMESO
      Mesoblast Files 2026 Form 20-F, Affirms Status as Well-Known Issuer

      Tipranks Press Release.

      Aug 27The Globe and MailMESO
      Mesoblast Flags Risks Around 2026 Outlook and Stem Cell Strategy

      Detailed price information for Mesoblast Ltd (MEOBF) from The Globe and Mail including charting and trades.

      Aug 27The Globe and MailMESO
      Mesoblast Fiscal 2026 Loss Narrows, Revenue Rises
      Aug 27Yahoo FinanceMESO
      Mesoblast Reports Substantial Revenue Growth to US$120M

      RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment

      Aug 27BarchartMESO
      Mesoblast H2 Earnings Call Highlights

      Mesoblast (NASDAQ:MESO) reported $115 million in net revenue for fiscal 2026, its first full year of commercial sales for RYONCIL, the company’s FDA-approved allogeneic mesenchymal stromal cell therapy for children with steroid-refractory acute graft-versus-host disease, or GVHD. Chief Executive Of

      Aug 27Yahoo FinanceMESO
      Mesoblast FY2026 slides: $115M revenue marks commercial transition
      Aug 27Investing.comMESO
      Earnings call transcript: Mesoblast posts $115 million in FY2026 revenue, stock slips
      Aug 26Investing.comMESO
      Full Transcript: Mesoblast FY 2026 Earnings Call
      Aug 26BenzingaMESO
      Mesoblast Reports Substantial Revenue Growth to US$120M

      RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment Financial Results and Operational Update for Full Year Ended June 30, 2026 NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2026 (FY2026). Chief Executive of Mesoblast Dr. Silviu Itescu, commented on the result: “We are very p

      Aug 26Yahoo FinanceMESO
      Mesoblast Issues 875,000 Unquoted Employee Incentive Options

      Tipranks Press Release.

      Aug 25The Globe and MailMESO
      Mesoblast Financial Results and Corporate Update Webcast

      NEW YORK, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the...

      Aug 24BarchartMESO

      This is the newest page. Registered accounts read further back.